^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M + EGFR C797S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Stevens-Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
Published date:
11/30/2023
Excerpt:
Four EGFR mutations 19 del/T790M/C797S in trans and cis were detected after osimertinib resistance….The patient received osimertinib and anlotinib after recovery, and SJS has not recurred. The ongoing treatment is still effective and results in stable disease.
DOI:
10.3389/fphar.2023.1131703
